Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu, Chantal MD *,1; Bode, Bruce W. MD 2; Franek, Edward MD 3; Philis-Tsimikas, Athena MD 4; Rose, Ludger MD 5; Graungaard, Tina MSc 6; Birk Osterskov, Anne MD 7; Russell-Jones, David MD 8
Diabetes, Obesity & Metabolism.
20(5):1148-1155, May 2018.
(Format: HTML, PDF)